Noshin Noorjahan

[Anticancer Research] Scientists investigated the possibility of selective redox-mediated treatment of TNBC cells by fenbendazole without affecting the viability and redox status of normal breast epithelial cells.

[Anticancer Research] Researchers evaluated the combined effect of monocarboxylate transporter inhibitors and 4-hydroxytamoxifen using the estrogen receptor-positive breast cancer cell line MCF-7, under normal glucose conditions.

[Anticancer Research] Pre-clinical studies highlighted various antitumor activities of plant-derived Cannabis sativa and synthetic cannabinoids (CBs). However, some studies indicated that CBs might also promote tumor progression. The authors review known and possible interactions between cannabinoids and TNBC therapies.

[AstraZeneca] AstraZeneca and Daiichi Sankyo’s Enhertu has been approved in China as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.

[Angewandte Chemie-International Edition] Investigators reported the identification of 979 proteins acylated with O-linked β-N-acetylglucosamine (O-GlcNAc) and 1,340 modification sites in mESCs by using a chemoproteomics method.

[Journal of Hazardous Materials] To study development toxicity of tetrabromobisphenol A, the proliferation toxicity was investigated using hESCs exposed to the lowest effective dose of two tetrabromobisphenol A analogs.